Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, announced that Dr. Neal Walker, President and CEO, will present a company overview virtually at the H.C. Wainwright Global Investment Conference. The presentation will be accessible starting May 24, 2022, at 7:00 a.m. ET. Additionally, management will conduct 1x1 virtual meetings on May 23. This event marks a significant opportunity for investors and stakeholders to gain insights into Aclaris’ innovative drug candidates aimed at immuno-inflammatory diseases. The presentation will be archived on Aclaris’ website for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
In the trading session that priced this news, ACRS gained 3.57%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the day for virtual 1x1 meetings.
A webcast of the presentation may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
